poliovirus

In his weekly clinical update, Dr. Griffin discusses the harms of perpetuating the lab leak hypothesis and the recent ACIP recommendations for the RSV vaccine for those individuals over 60, before reviewing the recent statistics on SARS-CoV-2 infection, treatment guidelines for the different phases of COVID, including vaccines, Pemgarda, early treatment with Paxlovid, remdesivir and molnupiravir, steroids at the right time, anticoagulation support, immune modulation in some cases, and a comprehensive definition of long COVID.

In his weekly clinical update, Dr. Griffin discusses how the pandemic may have effected our trust in physicians and hospitals and if waiting longer to make strain selection for the seasonal influenza vaccine would be advantageous before reviewing the recent statistics on SARS-CoV-2 infection, how different CVODI-19 vaccines effect the cardiovascular system, if the a third of either COVID-19 mRNA vaccine is effective, where to find PEMGARDA, if convalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, and the long term consequences of a SARS-CoV-2 infection on human health including incidences of diabetes, respiratory problems, hearing loss and maternal-fetal health.

In his weekly clinical update, Dr. Griffin discusses Merck’s RSV preventative monoclonal antibody Clesrovimab before reviewing the recent statistics on SARS-CoV-2 infection, if previous SARS-COV-2 infections predict the outcome of subsequent infections, if using COVID rapid diagnostic tests is cost effective, if the protein based vaccine NVX-CoV2327 elicits a durable immune response, if combination treatment of vaccine and antiviral drugs effectively protect against hospitalization, where to find PEMGARDA, what do when healthcare workers succumb to SARS-CoV-2 infection, and how COVID-19 may alter the cognitive trajectories of older patients.

In his weekly clinical update, Dr, Daniel Griffin reviews President Biden’s case of COVID, reviews recent statistics on SARS-CoV-2 infection, discusses post-acute sequelae after infection during pregnancy, the use of nirmatrelvir-ritonavir for post-exposure prophylaxis, where to find Pemgarda, effectiveness of combined nirmatrelvir-ritonavir-molnupiravir treatment, effectiveness of Ensitrelvir in reducing severe outcomes in outpatients at high risk for COVID-19, effectiveness of combined nirmatrelvir-ritonavir-molnupiravir treatment in patients hospitalized with COVID-19, CDC update of Long COVID Basics page, postacute sequelae of SARS-CoV-2 infection in the pre-delta, delta, and omicron eras, Long COVID risk has dropped over time but remains substantial, efficacy of antivirals, corticosteroids, and mAbs as acute COVID treatments in reducing the incidence of long COVID, and the interplay between diet and the gut microbiome: implications for health and disease.

In his weekly clinical update, Dr. Griffin discusses H5N1 influenza in the bird and cow communities of Colorado and Michigan and dengue in New York and the US before reviewing the recent statistics on SARS-CoV-2 infection, the absence of association with proton pump inhibitors and COVID-19 severity in children, where to find PEMGARDA, the effectiveness of molnupiravir and dexamethasone, convalescent plasma, what to do when healthcare workers succumb to SARS-CoV-2 infection, a resource of long COVID answers, how the WHO and CDC define long COVID and how it compares to ME/CSF.

In his weekly clinical update, Dr. Griffin discusses the fourth US case of H5N1 human infection and reminds the audience of the definition of “pasteurization” before reviewing the recent statistics on SARS-CoV-2 infection, where to find PEMGARDA, the effectiveness of molnupiravir and dexamethasone, convalescent plasma, what to do when healthcare workers succumb to SARS-CoV-2 infection, how an EEG can be used to look for signatures of cognitive decline after SARS-CoV-2 infection and what we observed 2 years following SARS-CoV-2 infection for tissue-resident T cell and viral RNA persistence.

In his weekly clinical update, Dr. Griffin discusses RSV vaccination recommendations and revisions to guidelines before reviewing the recent statistics on SARS-CoV-2 infection, data suggesting that individuals with high HLA-DQA2 expression (MHC class II) are…

In his weekly clinical update, Dr. Griffin reviews the recent statistics on SARS-CoV-2 infection, before discussing methods for sterilizing filtering facepieces, an update to the fall COVID boosters, the emergency use application of a pre-exposure prophylactic and where to find it and drug interaction database, convalescent plasma, the effectiveness of the monoclonal antibody sotrovimab against Omicorn variants, what to do when healthcare workers succumb to SARS-CoV-2 infection, the need for better nursing resources, how survivors of COVID-19-associated ARDS exhibited sustained elevation in endothelial dysfunction biomarkers, correlating with the severity of impaired gas exchange, reactivation of latent CMV as a consequence of a SARS-CoV-2 infection, identification of variables that might impact or predict a person’s time to recovery from an acute SARS-CoV-2 infection and if COVID-19 patients really have olfactory dysfunction more often than normally smelling individuals.